Article: Archimedes Pharma Announces Ground-Breaking Phase III Data Showing NasalFent to be Superior to the Standard of Care for Breakthrough Cancer Pain.

Article: BDSI Secures $7 Million Financing Commitment For Development of ...
Business Wire;  July 18, 2005 ;     700+ words ... ... million in funding for Phase III clinical trials relating ... for "breakthrough" cancer pain, meaning episodes of ... it intends to initiate Phase III trials of BEMA(TM ... treating breakthrough cancer pain represents significant ...

Article: WEX Receives No Objection Letter From Health Canada for ...
CCNMatthews Newswire;  June 13, 2007 ;     700+ words ... ... Health Canada for conducting a Phase III clinical trial in cancer pain for its lead product, Tectin ... The approval for conducting a Phase III study is a significant step ... additional fund to support this Phase III clinical trial. In the meantime ...

Article: WEX Starts Phase III Trial of Tectin(TM) for ...
CCNMatthews Newswire;  April 8, 2008 ;     700+ words ... ... of the first patient in a Phase III clinical trial of Tectin ... lead product candidate, for cancer pain. This clinical trial (TEC ... previous Phase IIB trial in cancer pain (WEX-014) and extensive ... to market Tectin(TM) for cancer pain. The clinical trials will ...

Article: Archimedes Pharma Announces Ground Breaking Phase ...
PR Newswire Europe;  May 8, 2009 ;     700+ words ... ... announces new positive headline phase III results for NasalFent(R ... rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to ... medicine for breakthrough cancer pain. Breakthrough cancer pain ...

Article: First Phase III Data Positive With BDSI's Buccal ...
BIOWORLD Today;  November 3, 2009 ;     700+ words ... ... fentanyl disc in a Phase III study for breakthrough cancer pain sent shares rocketing ... subjects in the Phase III study were enrolled ... with breakthrough cancer pain are getting treatment ... buzz is about cancer pain. The Phase III trial with ...

Article: BDSI's Phase III Buccal fentanyl data ...
BioWorld Week;  April 30, 2007 ;     563 words ... ... Morrisville, N.C.-based BioDelivery Sciences International Inc.'s polymer fentanyl disc in a Phase III study for breakthrough cancer pain sent shares rocketing skyward--and brought BDSI another step closer to taking on Cephalon Inc ...

Article: Javelin begins dosing in PMI-150 cancer pain ...
Pharma Marketletter;  August 6, 2007 ;     619 words ...Massachusetts, USA-based Javelin Pharmaceuticals says it has begun patient dosing in a Phase III trial of its cancer pain medication PMI-150 (intranasal ketamine). The study, which is being conducted at the Beth Israel Deaconess ...